Coreline Soft is strengthening its presence in the European medical AI market through a partnership with Germany-based Raya Diagnostics, as lung cancer screening enters a new phase of institutional adoption across the region.
The company announced on March 31 that it will collaborate with
Raya Diagnostics to expand access to AI-powered lung cancer screening across the DACH region, including Germany, Austria, and Switzerland. The partnership will integrate Coreline Soft’s AI solutions into Raya’s radiology platform, RayaONE, embedding them directly into existing RIS/PACS workflows and enabling scalable deployment across radiology networks.
The move follows
Germany’s Federal Joint Committee (G-BA) decision to approve national health insurance coverage for low-dose CT lung cancer screening. The policy is expected to accelerate screening demand while significantly increasing the importance of follow-up management and quality assurance (QA) within national screening programs.
As lung cancer screening becomes institutionalized across Europe, the role of AI is evolving beyond image analysis toward supporting end-to-end screening operations. Given the long-term nature of screening programs, which require continuous follow-up and patient management, operational elements such as nodule tracking, follow-up interval decisions, discrepancy resolution, and reporting standardization are becoming increasingly critical.
In response, AI solutions are expanding to include triage, structured reporting, automated tracking metrics, and quality assurance support. This shift reflects a broader transition toward “operational AI,” where technologies support not only detection accuracy but also the full lifecycle of screening programs.
Leading hospitals, including institutions such as Charité in Germany, are playing a central role in establishing standardized protocols that are subsequently adopted by regional imaging centers. With reimbursement now in place, Germany is experiencing increased screening volumes alongside stricter requirements for follow-up management and quality control, further driving demand for integrated AI solutions.
Through this partnership, Coreline Soft and Raya Diagnostics aim to extend guideline-aligned screening environments beyond large hospitals to smaller and mid-sized imaging centers. By embedding AI outputs directly into existing clinical workflows rather than using standalone systems, the companies seek to improve usability and accelerate network-wide adoption.
Across Europe, a combination of radiology workforce shortages and rising screening demand is intensifying the need for scalable, high-quality screening systems. Smaller centers, in particular, face greater gaps in specialized expertise, making access to standardized tools a key competitive factor.
At the same time, policy developments such as the expansion of the UK’s NHS screening programs, Germany’s reimbursement rollout, and France’s integration into public healthcare infrastructure are reshaping the European lung cancer screening landscape. Competitive dynamics are shifting away from standalone AI accuracy toward alignment with national screening systems, multi-center operability, quality management, and data standardization capabilities.
Coreline Soft is strengthening its infrastructure through its AVIEW HUB platform, which supports multi-center reading, quality control, and data anonymization. Industry analysts note that these operational capabilities are increasingly emerging as key barriers to entry in the evolving European medical AI market.
2026.03.31
List